Literature DB >> 18495634

Doctors' versus patients' global assessments of treatment effectiveness: empirical survey of diverse treatments in clinical trials.

Evangelos Evangelou1, Georgios Tsianos, John P A Ioannidis.   

Abstract

OBJECTIVE: To examine whether doctors' global assessments of treatment effects agree with patients' global assessments.
DESIGN: Survey of trials included in systematic reviews of treatments for diverse conditions. DATA SOURCES: Cochrane database of systematic reviews. Data extracted Data on patients' global assessments and on doctors' global assessment for the same treatment against the same comparator. MAIN OUTCOME MEASURES: Relative odds ratio (ratio of odds ratios of global improvement with the experimental intervention versus control according to doctors compared with patients), and improvement rates according to doctors and patients.
RESULTS: Doctors' global assessments were compared with patients' global assessments for 63 different treatment comparisons (240 trials) in 18 conditions. The summary relative odds ratio across the comparisons was not significant (0.98, 95% confidence interval 0.88 to 1.08; I(2)=0%, 95% confidence interval 0% to 30%). In 62 of the 63 comparisons the effects of treatment rated by patients and by doctors did not differ beyond chance, but for single comparisons the confidence intervals were large. Rates of improvement on average did not differ between doctors' assessments and patients' assessments (summary relative odds ratio 0.98, 0.88 to 1.06; I(2)=0%, 0% to 24%).
CONCLUSION: Doctors' global assessments of the effects of treatments are on average similar to those of patients.

Entities:  

Mesh:

Year:  2008        PMID: 18495634      PMCID: PMC2413393          DOI: 10.1136/bmj.39560.759572.BE

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  23 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

2.  Statistical methods for assessing the influence of study characteristics on treatment effects in 'meta-epidemiological' research.

Authors:  Jonathan A C Sterne; Peter Jüni; Kenneth F Schulz; Douglas G Altman; Christopher Bartlett; Matthias Egger
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

3.  Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials.

Authors:  Ethan M Balk; Peter A L Bonis; Harry Moskowitz; Christopher H Schmid; John P A Ioannidis; Chenchen Wang; Joseph Lau
Journal:  JAMA       Date:  2002-06-12       Impact factor: 56.272

4.  Learning from discordance in patient and physician global assessments of systemic lupus erythematosus disease activity.

Authors:  C Neville; A E Clarke; L Joseph; P Belisle; D Ferland; P R Fortin
Journal:  J Rheumatol       Date:  2000-03       Impact factor: 4.666

5.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

6.  Opinions of patients with rheumatoid arthritis about their own functional capacity: how valid is it?

Authors:  J W Jacobs; F G Oosterveld; N Deuxbouts; J J Rasker; E Taal; J Dequeker; R Uytterhoeven
Journal:  Ann Rheum Dis       Date:  1992-06       Impact factor: 19.103

7.  Determinants of discordance between patients and physicians in their assessment of lupus disease activity.

Authors:  Jim C Yen; Michal Abrahamowicz; Patricia L Dobkin; Ann E Clarke; Renaldo N Battista; Paul R Fortin
Journal:  J Rheumatol       Date:  2003-09       Impact factor: 4.666

8.  Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy.

Authors:  S B Cohen; V Strand; D Aguilar; J J Ofman
Journal:  Rheumatology (Oxford)       Date:  2004-03-02       Impact factor: 7.580

9.  Further clues to recognition of patients with fibromyalgia from a simple 2-page patient multidimensional health assessment questionnaire (MDHAQ).

Authors:  D A DeWalt; G W Reed; T Pincus
Journal:  Clin Exp Rheumatol       Date:  2004 Jul-Aug       Impact factor: 4.473

10.  An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.

Authors:  T Pincus; V Strand; G Koch; I Amara; B Crawford; F Wolfe; S Cohen; D Felson
Journal:  Arthritis Rheum       Date:  2003-03
View more
  6 in total

1.  Assessing patients' improvement in clinical trials.

Authors:  John Spertus
Journal:  BMJ       Date:  2008-05-21

2.  Adverse effects of antipsychotic drugs: survey of doctors' versus patients' perspective.

Authors:  Michela Nosè; Maria Angela Mazzi; Eleonora Esposito; Marco Bianchini; Paola Petrosemolo; Giovanni Ostuzzi; Michele Tansella; Corrado Barbui
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-11-28       Impact factor: 4.328

3.  Relative effectiveness and adverse effects of cervical manipulation, mobilisation and the activator instrument in patients with sub-acute non-specific neck pain: results from a stopped randomised trial.

Authors:  Hugh Gemmell; Peter Miller
Journal:  Chiropr Osteopat       Date:  2010-07-09

4.  Quantifying clinical change: discrepancies between patients' and providers' perspectives.

Authors:  Rachel P Dreyer; Philip G Jones; Shelby Kutty; John A Spertus
Journal:  Qual Life Res       Date:  2016-03-19       Impact factor: 4.147

5.  A systematic appraisal of allegiance effect in randomized controlled trials of psychotherapy.

Authors:  Elena Dragioti; Ioannis Dimoliatis; Konstantinos N Fountoulakis; Evangelos Evangelou
Journal:  Ann Gen Psychiatry       Date:  2015-09-15       Impact factor: 3.455

6.  Self-rated treatment outcomes in medical rehabilitation among German and non-German nationals residing in Germany: an exploratory cross-sectional study.

Authors:  P Brzoska; O Sauzet; Y Yilmaz-Aslan; T Widera; O Razum
Journal:  BMC Health Serv Res       Date:  2016-03-28       Impact factor: 2.655

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.